•
US-based biopharmaceutical company I-Mab (NASDAQ: IMAB) has announced the appointment of Sean (Xi-Yong) Fu, PhD, MBA, as its permanent Chief Executive Officer (CEO), effective November 1, 2024. Dr. Fu, who has been serving as Interim CEO since July 15, 2024, will also continue his role as a member of the…
•
Denmark-based pharmaceutical company Novo Nordisk A/S (NYSE: NVO) has released its financial results for the third quarter of 2024. The company reported revenues of DKK 204.72 billion (USD 29.459 billion) for the first nine months, marking a 24% year-on-year (YOY) growth in constant currency terms. Diabetes and Obesity Care Drive…
•
At the 7th China International Import Expo (CIIE), China-based Shanghai Pharmaceutical Co., Ltd (SPH, SHA: 601607, HKG: 2607) announced a series of partnerships with prominent pharmaceutical companies, spanning domestic and international entities. Expanding Collaborations in Pharmaceutical InnovationFrance’s Sanofi (NASDAQ: SNY) has agreed to deepen its existing partnership with SPH, initially…
•
Germany-based medical device giant Siemens Healthineers AG (ETR: SHL) has released its financial results for the fourth quarter of fiscal 2024, ended September 30, 2024, and the full fiscal year 2024. The company achieved its targets for revenue growth and earnings per share for FY2024, demonstrating resilience amidst challenging market…
•
China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced plans to present new and updated data from the sovleplenib ESLIM-01 Phase III trial, along with several investigator-initiated studies of compounds discovered by HutchMed, at the American Society of Hematology (ASH) Annual Meeting and the European Society for Medical Oncology…
•
German pharmaceutical giant Bayer HealthCare (FRA: BAYN) has entered into a partnership agreement with the China Population Welfare Foundation (CPWF) at the 7th China International Import Expo (CIIE). The collaboration aims to enhance public health awareness by promoting health science popularization and advocacy activities. Joint Focus on Health Initiatives Under…
•
US-Irish firm Medtronic (NYSE: MDT) has entered into a partnership with China-based China Resources Guangdong Pharmaceutical Co., Ltd. (HKG: 3320) at the 7th China International Import Expo (CIIE). The collaboration is aimed at developing minimally invasive surgical medical equipment to enhance patients’ diagnosis and treatment experience. Focus on GBA Policy…
•
The National Medical Products Administration (NMPA) website has indicated that Pfizer’s (NYSE: PFE) marketing filing for Talzenna (talazoparib) has been approved, clearing the way for the poly ADP-ribose polymerase (PARP) inhibitor to treat metastatic castration-resistant prostate cancer (mCRPC) in China. Talazoparib’s Global Approvals and IndicationsTalazoparib received approval in the US…
•
Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) has announced a strategic adjustment regarding its drug candidate SY-1530. The company has decided to proactively terminate the clinical development of the BTK inhibitor as a monotherapy for recurrent/refractory mantle cell lymphoma (MCL) and other B-cell derived non-Hodgkin lymphoma (B-NHL). Despite this,…
•
Nanjing Leads Biolabs Co., Ltd, a China-based biopharmaceutical company, has announced that it has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for its Category 1 drug LBL-034, which is intended for the treatment of multiple myeloma (MM). LBL-034: A Novel Bispecific Antibody Targeting GPRC5D…
•
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that it has received marketing approval from the European Medicines Agency (EMA) for its drug Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children aged one to 11 years who weigh at least 15 kg. The approval covers patients who are inadequately…
•
At the 7th China International Import Expo (CIIE), Swiss pharmaceutical giant Novartis (NYSE: NVS) announced strategic partnerships with US medical device and life sciences company GE Healthcare Technologies Inc., (NASDAQ: GEHC), and Chinese firms Shanghai Pharmaceuticals Holding Co., Ltd (HKG: 2607, SHA: 601607; SPH) and C.Q. Pharmaceutical Holding Co., Ltd…
•
Vantive, a planned spin-off from U.S.-based Baxter International (NYSE: BAX) specializing in kidney care, has entered into separate collaboration agreements with the Chinese unit of UK’s Kertone Ltd. and Hangzhou Qiantang Longyue Biotechnology Co., Ltd. at the 7th China International Import Expo (CIIE). These partnerships focus on hemodialysis and peritoneal…
•
US biotechnology company Amgen (NASDAQ: AMGN) has announced that it has received market approval in China for its drug Tavneos (avacopan). The National Medical Products Administration (NMPA) has approved Tavneos for use as adjuvant therapy in adults with severe and active anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, specifically granulomatous polyangitis…
•
US major Boston Scientific Corporation (NYSE: BSX) has officially launched its Vercisie Genius, an implantable deep brain stimulation (DBS) system, at the 7th CIIE. This move is set to enhance the treatment options available to China’s growing Parkinson’s disease (PD) population. Parkinson’s Disease and Deep Brain Stimulation TherapyParkinson’s disease (PD),…
•
CARSgen Therapeutics Holdings Ltd (HKG: 2171), a China-based specialist in chimeric antigen receptor (CAR)-T cell therapies, has announced the presentation of the latest data for its CAR-T therapies, CT053 (zevorcabtagene autoleucel; zevor-cel), CT071, and CT0590, at the 66th American Society of Hematology (ASH) annual meeting. CT053 Phase II Study Subgroup…
•
Changchun High & New Technology Industries (Group) Inc., (SHE: 000661), a leading China-based company, has announced that it has received another indication approval from the National Medical Products Administration (NMPA) for its polyethylene glycol recombinant human somatropin, a long-acting somatropin, for the treatment of idiopathic short stature (ISS). Understanding Idiopathic…
•
Huadong Medicine Co., Ltd (SHE: 000963), a China-based pharmaceutical company, has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its biosimilar version of Johnson & Johnson’s (J&J, NYSE: JNJ) auto-immune disease drug Stelara (ustekinumab), named SaiLeXin. This development marks a significant step forward…
•
China-based Northeast Pharmaceutical Co., Ltd (SHE: 000597) has announced its intention to acquire a 70% stake in Beijing Dingcheng Peptide Source Biotechnology Co., Ltd, a fellow Chinese firm, for a consideration of RMB 186.8 million. This strategic move is aimed at bolstering Northeast Pharmaceutical’s presence in the cell therapy sector.…
•
China-based Ascentage Pharma (HKG: 6855) has announced that it will present the results of multiple clinical studies for its olverembatinib (HQP1351) and three clinical studies for its lisaftoclax (APG-2575) at the 66th American Society of Hematology (ASH) annual meeting. These presentations highlight the company’s commitment to advancing treatments for various…